Source comparison
MT-1: Dosing, Reconstitution, Administration Comparison
Standard Vial Concentration 10mg lyophilized powder Both require reconstitution; neither is pre-mixed Reconstitution Volume 2mL bacteriostatic water (yields 5mg/mL) 1–2mL bacteriostatic water MT-1 protocols use higher injection volumes per dose Typical Dose Ra
This comparison does not assign a generated winner or score.
- Standard Vial Concentration
- 10mg lyophilized powder
- Both require reconstitution; neither is pre-mixed
- Reconstitution Volume
- 2mL bacteriostatic water (yields 5mg/mL)
- 1–2mL bacteriostatic water
- MT-1 protocols use higher injection volumes per dose
- Typical Dose Range
- 0.08–0.16mg/kg every 48 hours
- 0.01–0.02mg/kg daily
- MT-1 requires 8–10× higher mass per dose than MT-2
- Onset to Visible Pigmentation
- 5–10 days at therapeutic dose
- 3–7 days at therapeutic dose
- MT-2 onset is slightly faster due to non-selective receptor binding
- Duration to Maximal Effect
- 10–14 days
- 7–10 days
- Both require continuous dosing; single-dose effects are negligible
- Storage (Reconstituted)
- 2–8°C, use within 30 days
- Temperature excursions above 8°C denature both peptides irreversibly
- Injection Site
- Subcutaneous (abdomen or thigh)
- Both avoid intramuscular or intravenous routes
- Common Adverse Events
- Nausea (20–35%), flushing, injection site reaction
- Nausea (30–50%), spontaneous erections, flushing
- MT-1's MC1R selectivity reduces MC4R-mediated side effects
- FDA Approval Status
- Approved (as Scenesse implant for EPP)
- Not approved for any indication
- MT-1 is the only melanocortin analog with regulatory clearance
- MT-1 requires higher per-dose mass because of its lower potency per milligram compared to MT-2. A trade-off for receptor selectivity and reduced side effect burden. Researchers prioritizing minimal off-target activation select MT-1; those optimizing for rapid onset and lower material cost per study cycle select MT-2.